Mizuno Y - Search Results

1

p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

Mogi M, Kondo T, Mizuno Y, Nagatsu T. Mogi M, et al. Among authors: mizuno y. Neurosci Lett. 2007 Feb 27;414(1):94-7. doi: 10.1016/j.neulet.2006.12.003. Epub 2006 Dec 29. Neurosci Lett. 2007. PMID: 17196747

2

Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.

Mizuno Y, Kanazawa I, Kuno S, Yanagisawa N, Yamamoto M, Kondo T. Mizuno Y, et al. Mov Disord. 2007 Jan;22(1):75-80. doi: 10.1002/mds.21218. Mov Disord. 2007. PMID: 17094103 Clinical Trial.

3

Familial hemifacial spasm: report of cases and review of literature.

Miwa H, Mizuno Y, Kondo T. Miwa H, et al. Among authors: mizuno y. J Neurol Sci. 2002 Jan 15;193(2):97-102. doi: 10.1016/s0022-510x(01)00651-7. J Neurol Sci. 2002. PMID: 11790389 Review.

4

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Mizuno Y, et al. Mov Disord. 2013 Jul;28(8):1138-41. doi: 10.1002/mds.25418. Epub 2013 Mar 11. Mov Disord. 2013. PMID: 23483627 Free PMC article. Clinical Trial.

5

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.

Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M; Japanese Istradefylline Study Group. Mizuno Y, et al. Mov Disord. 2010 Jul 30;25(10):1437-43. doi: 10.1002/mds.23107. Mov Disord. 2010. PMID: 20629136 Clinical Trial.

6

Bell's palsy-induced blepharospasm.

Miwa H, Kondo T, Mizuno Y. Miwa H, et al. Among authors: mizuno y. J Neurol. 2002 Apr;249(4):452-4. doi: 10.1007/s004150200038. J Neurol. 2002. PMID: 11967652

7

Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N. Mizuno Y, et al. Clin Neuropharmacol. 2010 Jan-Feb;33(1):1-4. doi: 10.1097/WNF.0b013e3181bbf45c. Clin Neuropharmacol. 2010. PMID: 19935410

8

[Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].

Kondo T, Takubo H, Yokochi F, Okuma Y, Mizuno Y. Kondo T, et al. Among authors: mizuno y. No To Shinkei. 2002 Dec;54(12):1041-8. No To Shinkei. 2002. PMID: 12599519 Japanese.

9

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.

Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I; STRONG Study Group. Mizuno Y, et al. Mov Disord. 2007 Oct 15;22(13):1860-5. doi: 10.1002/mds.21313. Mov Disord. 2007. PMID: 17618525 Clinical Trial.

10

Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial.

Nomoto M, Mizuno Y, Kondo T, Hasegawa K, Murata M, Takeuchi M, Ikeda J, Tomida T, Hattori N. Nomoto M, et al. Among authors: mizuno y. J Neurol. 2014 Oct;261(10):1887-93. doi: 10.1007/s00415-014-7427-3. Epub 2014 Jul 15. J Neurol. 2014. PMID: 25022939 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,587 results

Search Page

Filters